Journal: Breast Cancer Research : BCR

Article Title: NOTCH1 inhibition enhances immunogenicity and sensitizes triple-negative breast cancer to immune checkpoint inhibitors

doi: 10.1186/s13058-025-02045-2

Figure Lengend Snippet: NOTCH1 inhibition therapy combined with ICIs exert impressive anti-tumor effects and promote immune responds. ( A ) Schematic representation of the in vivo vaccination assay drawn by Figdraw. ( B ) Tumor-free survival curves of BALB/c mice vaccinated with freeze-thawed or DAPT (180 μM) or Floxuridine (30 μM) treated 4T1-NICD cells ( n = 10). ( C - D ) Schematic of DAPT, BMS-1, ATM inhibitor and anti-IFNAR treatment in BALB/c mice models. Representative tumor images of mice, n = 6 for each group. ( E ) Average tumor volume in the mice over time was shown as growth curves. ( F ) Average tumor weight at the end of indicated treatment. ( G ) The change of mouse body weight in the process of treatment. ( H - I ) The ratio of tumor-infiltrating CD3 + CD8 + T cells and CD3 + CD4 + T cells. ( J ) The expression of NOTCH1, p-ATM, Ki67 and CD11b in mouse tumor tissues was detected by immunohistochemistry assays. Scale bars = 50 μm. * p < 0.05, ** p < 0.01 vs Control or DAPT + BMS-1 group

Article Snippet: The following antibodies were used: NOTCH1 (bs-1335R, Bioss), Ki-67 (28074–1-AP, Proteintech Group), CD11b (bs-1014R, Bioss).

Techniques: Inhibition, In Vivo, Expressing, Immunohistochemistry, Control